Year archive

3D Medicines Inc. — 2022 filings

All 15 regulatory filings released by 3D Medicines Inc. (1244) in 2022, sourced directly from the official regulator.

15 Filings

2022 Period

2022 filings (15)

Filing	Released	Lang
VOLUNTARY ANNOUNCEMENT A PHASE II STUDY PROTOCOL OF ENVAFOLIMAB FOR THE TREATMENT OF dMMR ADVANCED SOLID TUMORS HAS BEEN ALLOWED TO PROCEED BY U.S. FOOD AND DRUG ADMINISTRATION Regulatory Filings	2022-12-30	English
List of Directors and their Roles and Functions Board/Management Information	2022-12-13	English
Terms of Reference for the Remuneration Committee Remuneration Information	2022-12-13	English
Terms of Reference for the Nomination Committee Governance Information	2022-12-13	English
Terms of Reference for the Audit Committee Governance Information	2022-12-13	English
Amended and Restated Memorandum of Association Governance Information	2022-12-13	English
Announcement of Offer Price and Allotment Results Share Issue/Capital Change	2022-12-13	English
Documents on Display Regulatory Filings	2022-11-28	English
GREEN APPLICATION FORM Capital/Financing Update	2022-11-28	English
GLOBAL OFFERING Capital/Financing Update	2022-11-28	English
GLOBAL OFFERING Capital/Financing Update	2022-11-28	English
PHIP (1st submission) Audit Report / Information 9M 2022	2022-11-17	English
PHIP (1st submission) Regulatory Filings	2022-11-17	English
Application Proof (1st submission) Audit Report / Information FY 2021	2022-07-22	English
Application Proof (1st submission) Regulatory Filings	2022-07-22	English